198 related articles for article (PubMed ID: 12475665)
1. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Gretzer MB; Epstein JI; Pound CR; Walsh PC; Partin AW
Urology; 2002 Dec; 60(6):1034-9. PubMed ID: 12475665
[TBL] [Abstract][Full Text] [Related]
2. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
5. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
6. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
Freedland SJ; Sutter ME; Dorey F; Aronson WJ
Urology; 2003 Feb; 61(2):365-9. PubMed ID: 12597949
[TBL] [Abstract][Full Text] [Related]
7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
8. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
10. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
11. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
12. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
13. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
14. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
15. Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study.
Olumi AF; Richie JP; Schultz DJ; D'Amico AV
Urology; 2000 Aug; 56(2):273-7. PubMed ID: 10925093
[TBL] [Abstract][Full Text] [Related]
16. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
[TBL] [Abstract][Full Text] [Related]
17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
18. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
19. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
20. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage.
Shekarriz B; Upadhyay J; Wood DP; Hinman J; Raasch J; Cummings GD; Grignon D; Littrup PJ
Urology; 1999 Dec; 54(6):1044-8. PubMed ID: 10604706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
